Federal rescheduling has changed the tax outlook for the medical cannabis industry. Access to deductions and credits previously restricted by Section 280E may lower federal income tax liabilities and improve after-tax cash flow for affected businesses.
The cannabis rescheduling tax implications require careful analysis, particularly for companies operating in both medical and adult-use markets. They also raise a broader question: how should a business use additional cash made available from rescheduling?
Understanding the Changes
Effective April 28, 2026, a federal final rule placed FDA-approved drug products containing marijuana and marijuana subject to a state medical marijuana license in Schedule III of the Controlled Substances Act. Marijuana outside those categories remains in Schedule I, while broader marijuana rescheduling is being addressed through a separate federal process.
Section 280E of the Internal Revenue Code generally disallows deductions and credits for businesses trafficking in Schedule I or II controlled substances in violation of federal or state law. The final rule states that holders of state medical marijuana licenses will no longer be subject to that deduction disallowance, although the rule does not determine any individual taxpayer’s federal tax liability.
Treasury and the IRS have said they expect the order to have significant positive tax consequences for medical marijuana businesses. Forthcoming guidance is expected to address companies with multiple activities, including the apportionment of expenses between activities related to trafficking in Schedule I or II controlled substances and activities that fall outside Section 280E as a result of the order.
This distinction is especially important for companies with both medical and adult-use operations. Products, licenses, revenue streams, costs and shared expenses may require separate analysis rather than uniform treatment across the organization.
Before changing a tax or financial reporting position, affected businesses should confirm how the final rule applies to their activities and whether their documentation supports the proposed treatment.
Retroactive Relief Remains a Possibility
The final rule also encourages Treasury to consider “retrospective relief” from Section 280E for taxable years in which a state licensee operated under a state medical marijuana license. The rule does not authorize prior-year refunds or establish a process for claiming them.
Treasury has indicated that anticipated guidance is expected to include a transition rule under which rescheduling generally applies to the full taxable year containing the final order’s effective date for activities that no longer involve Schedule I or II substances because of the order. That transition-year treatment is separate from possible relief for earlier taxable years.
If Treasury ultimately allows retroactive relief, affected businesses may be able to consider amended returns, refund claims or other tax adjustments. However, it is important to treat this relief as potential upside rather than committed capital.
Companies can still prepare by preserving returns and workpapers, documenting applicable medical licenses, reviewing support for medical and adult-use activities, identifying potentially open taxable years and modeling possible outcomes.
What’s Next: Assess Your Business Before Allocating Capital
The tax implications of cannabis rescheduling are only part of the story. The more important question is what comes next. Any improvement in after-tax cash flow should begin with an assessment, not a spending decision.
Management needs an accurate picture of the company’s operating performance, balance sheet and near-term obligations. The review should examine:
- Margins and recurring expenses
- Debt terms and other financial obligations
- Working capital requirements
- Inventory management and operational processes
- Infrastructure and technology needs
- The systems supporting medical and adult-use activities
It should also identify expenses that can be reduced or redirected before the company commits additional capital.
The results should reveal where the business is carrying unnecessary risk, losing value or limiting its ability to scale. Reliable forecasts, margin data and cash-flow reporting are essential to comparing potential uses of funds and evaluating whether an investment is likely to produce an adequate return.
For companies with both medical and adult-use operations, reporting capabilities deserve immediate attention. Accounting systems should be able to identify products, revenue, costs and shared expenses by activity. Treasury has already identified expense apportionment for businesses with multiple activities as an area for forthcoming guidance. A company that cannot support those distinctions has found its first priority.
Compare Competing Uses of Capital
How a company deploys additional cash will often matter more than the amount itself.
A company carrying expensive debt should approach the opportunity differently from one with a strong balance sheet and an immediate capacity constraint. For the first, debt reduction may provide the clearest near-term return. The second may find greater value in systems, equipment or another operating investment.
A practical capital-allocation review should compare three priorities:
- Stabilizing the balance sheet: Address high-cost debt, near-term obligations, working capital needs and appropriate operating reserves.
- Strengthening the operating platform: Correct weaknesses in financial reporting, inventory controls, technology, infrastructure or staffing.
- Positioning the company for growth: Consider expansion, additional capacity and acquisitions after confirming that the business can support them.
The company’s financial condition, operating constraints and available opportunities will dictate prioritization.
Address Debt and Near-Term Obligations
Cannabis businesses have often relied on costly or restrictive financing. Paying down high-cost debt can reduce interest expense, strengthen the balance sheet and increase future cash generation.
Companies should review borrowing costs, upcoming maturities, prepayment terms, covenant requirements and refinancing alternatives. Debt reduction is not always the best answer, but its predictable return should be compared with the expected return and risk of other investments.
Working capital also deserves attention. Stronger reserves can help fund payroll, inventory purchases, tax obligations, capital expenditures and unexpected operating needs without increasing dependence on outside financing. Make sure the balance sheet can support growth before committing capital to it.
Strengthen the Operating Platform
Some companies will produce a greater return by addressing an operational constraint. Investments in accounting systems, inventory controls, technology, facilities or key personnel can improve efficiency and prepare the organization for growth.
Each proposed investment needs a defined purpose. Management should know how the expenditure will improve capacity, lower costs, strengthen reporting or produce a measurable operating benefit.
For many cannabis operators, this is also an opportunity to build the financial and operating infrastructure needed to support the company’s next stage of growth. More reliable reporting, formalized processes and stronger controls can improve decision-making internally and prepare the business for scrutiny from lenders, investors or prospective buyers.
Companies with medical and adult-use operations should also ensure that their accounting processes support consistent and defensible expense allocations. These capabilities could become even more important if retroactive relief becomes available and prior-year activity must be evaluated or reconstructed.
Evaluate Growth Opportunities
Once the company has assessed its financial and operational position, additional cash flow may support expansion, capacity investments or acquisitions.
Uneven financial effects across the industry may contribute to additional transaction opportunities, particularly where operators are already reassessing markets, licenses or underperforming assets. This possibility should be treated as an industry observation, not a guaranteed consequence of rescheduling.
Companies considering an acquisition should compare the economics of buying an existing asset with building the capability internally, since an attractive purchase price does not necessarily make an acquisition a sound investment. This analysis should account for purchase price, development time, license considerations, historical tax exposure, working capital requirements, integration costs and the reliability of the target’s financial information.
A target may carry unresolved tax, accounting, operational or regulatory risks. Internal development may require more time and capital than initial projections suggest. Both paths require a clear understanding of the full cost, expected return and effect on the existing business.
Additional capital does not reduce the need for financial, tax and operational due diligence. It raises the stakes of getting that analysis right.
Prepare for Further Industry Changes
Medical marijuana rescheduling is one part of the cannabis industry’s continuing evolution, while broader rescheduling remains in a separate federal process. Banking access, capital-market developments and institutional participation are also key areas to monitor.
The immediate priority is to strengthen the business under current conditions. Accurate financial reporting, supportable forecasts, effective internal controls, reliable inventory information and well-documented tax positions will help companies evaluate future opportunities with greater confidence.
For businesses in both medical and adult-use markets, readiness also depends on the ability to separate activities accurately and defend the methodology used. Strong accounting processes support tax compliance, capital planning and transaction readiness.
Looking Ahead
Cannabis rescheduling has created important tax and planning considerations for qualifying medical cannabis businesses—with the potential for retroactive relief dependent on Treasury guidance. In the meantime, companies should focus on where additional financial flexibility can create the greatest long-term value.
To discuss how to evaluate and prioritize the opportunities created by rescheduling, contact Grassi’s Cannabis Advisors.
Disclaimer: This article is provided for general informational purposes only and does not constitute tax, legal or accounting advice.
FAQ: Cannabis Rescheduling and Financial Planning
How does cannabis rescheduling affect Section 280E?
Qualifying activities involving marijuana subject to a state medical marijuana license may no longer face Section 280E restrictions on deductions and credits. Businesses should confirm how the final rule applies before changing their tax treatment or financial reporting.
Does cannabis rescheduling apply to medical and adult-use businesses?
The federal rule applies to qualifying medical marijuana activities, not adult-use activities. Businesses operating in both markets may need to separate products, revenue, costs and shared expenses to support the appropriate tax treatment.
Can medical cannabis businesses claim retroactive tax relief?
Not currently. Treasury has been encouraged to consider retroactive Section 280E relief, but no refund or amended-return process has been established. Businesses should not treat potential refunds as available capital.
How can cannabis businesses prepare for potential retroactive relief?
Businesses should preserve tax returns and workpapers, document medical licenses, identify open taxable years and review support for medical and adult-use activities. They can also model potential outcomes while awaiting federal guidance.
What should cannabis businesses do with additional cash flow from rescheduling?
Businesses should first assess debt, working capital, operating performance, reporting systems and near-term obligations. Additional cash should be directed toward opportunities that offer an appropriate balance of return, risk and long-term value.
What should cannabis businesses do while awaiting further federal guidance?
Businesses should strengthen tax documentation, forecasting, internal controls, inventory reporting and accounting processes. Operators serving both medical and adult-use markets should prioritize consistent and supportable expense-allocation methods.
Should a cannabis business pay down debt or invest in growth?
The decision depends on the company’s financial condition. Paying down high-cost debt may provide a predictable return, while a financially stable business may benefit more from investments in systems, equipment, infrastructure or growth.
Why is financial reporting important after cannabis rescheduling?
Accurate reporting helps businesses support tax positions, forecast cash flow and compare investment options. Companies with medical and adult-use operations should also be able to separate revenue, costs and shared expenses by activity.
How should cannabis businesses evaluate growth opportunities?
Businesses should evaluate the full cost, expected return and risk of each opportunity. Expansion and acquisition decisions should consider regulatory requirements, historical tax exposure, working capital, financial controls and integration costs.
